[	O
Inhibitory	O
effect	O
of	O
adenovirus	O
-	O
mediated	O
endostatin	O
gene	O
transfer	O
on	O
transplanted	O
lung	B-Cancer
carcinoma	I-Cancer
in	O
mice	O
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
adenovirus	O
-	O
mediated	O
endostatin	O
gene	O
transfer	O
on	O
transplanted	O
lung	B-Cancer
cancer	I-Cancer
in	O
mice	O
and	O
its	O
mechanism	O
of	O
action	O
.	O

METHODS	O
:	O
Transplant	B-Cancer
tumor	I-Cancer
model	O
was	O
induced	O
by	O
subcutaneous	B-Immaterial_anatomical_entity
inoculation	O
of	O
2	O
x	O
10	O
(	O
6	O
)	O
Lewis	B-Cell
lung	I-Cell
cancer	I-Cell
(	I-Cell
LLC	I-Cell
)	I-Cell
cells	I-Cell
into	O
the	O
back	B-Organism_subdivision
of	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
mice	O
were	O
treated	O
by	O
intratumoral	B-Cancer
injection	O
of	O
2	O
x	O
10	O
(	O
9	O
)	O
pfu	O
Ad	O
-	O
mEndostatin	O
.	O

The	O
expression	O
of	O
endostatin	O
in	O
situ	O
and	O
its	O
maintaining	O
time	O
were	O
detected	O
by	O
immunohistochemistry	O
and	O
Western	O
Blot	O
,	O
respectively	O
.	O

The	O
endostatin	O
level	O
in	O
serum	B-Organism_substance
was	O
determined	O
by	O
ELISA	O
.	O

The	O
inhibition	O
of	O
tumor	B-Cancer
growth	O
and	O
changes	O
of	O
survival	O
were	O
recorded	O
and	O
the	O
microvessel	B-Tissue
density	O
(	O
MVD	O
)	O
was	O
determined	O
by	O
histochemical	O
stainingwith	O
CD31	O
and	O
CD105	O
antibodies	O
.	O

The	O
tumor	B-Cancer
apoptosis	O
was	O
observed	O
by	O
electron	O
microscopy	O
.	O

RESULTS	O
:	O
In	O
comparison	O
with	O
controls	O
,	O
intratumoral	B-Cancer
injection	O
of	O
Ad	O
-	O
mEndostatin	O
significantly	O
inhibited	O
the	O
tumor	B-Cancer
growth	O
and	O
metastasis	O
,	O
and	O
prolonged	O
the	O
survival	O
rate	O
of	O
mice	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Strong	O
positive	O
expression	O
of	O
mEndostatin	O
was	O
seen	O
in	O
the	O
tumor	B-Tissue
tissue	I-Tissue
after	O
injection	O
of	O
Ad	O
-	O
mEndostatin	O
,	O
immunhistochemically	O
ostained	O
by	O
mouse	O
endostatin	O
monoclonal	O
antibody	O
,	O
while	O
the	O
control	O
groups	O
showed	O
only	O
very	O
low	O
expression	O
or	O
absence	O
.	O

Serum	B-Organism_substance
endostatin	O
concentration	O
was	O
1540	O
+	O
/	O
-	O
560	O
ng	O
/	O
ml	O
at	O
the	O
second	O
week	O
of	O
administration	O
,	O
the	O
expression	O
of	O
endostatin	O
diminished	O
a	O
month	O
later	O
.	O

The	O
microvessel	B-Tissue
density	O
(	O
MVD	O
)	O
)	O
decreased	O
from	O
42	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
8	O
to	O
10	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
2	O
per	O
x	O
200	O
magnificetion	O
microscopic	O
field	O
by	O
CD10	O
staining	O
and	O
from	O
68	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
5	O
to	O
37	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
6	O
by	O
CD31	O
staining	O
,	O
respectively	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

More	O
apoptotic	O
tumor	B-Cell
cells	I-Cell
were	O
seen	O
under	O
the	O
transmission	O
electron	O
microscope	O
.	O

CONCLUSION	O
:	O
Endostatin	O
gene	O
therapy	O
mediated	O
by	O
adenoviral	O
vector	O
efficiently	O
induces	O
expression	O
of	O
endostatin	O
in	O
vivo	O
,	O
and	O
inhibits	O
the	O
growth	O
and	O
metastasis	O
of	O
tumor	B-Cancer
.	O

It	O
is	O
concluded	O
that	O
its	O
action	O
is	O
targeted	O
to	O
tumor	B-Multi-tissue_structure
neovasculature	I-Multi-tissue_structure
and	O
the	O
mechanism	O
is	O
inhibition	O
of	O
tumor	B-Cancer
angiogenesis	O
.	O

